Financhill
Back

Novavax 10K Form

Sell
27

NVAX
Novavax

Last Price:
4.84
Seasonality Move:
22.51%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

Receive NVAX News And Ratings

See the #1 stock for the next 7 days that we like better than NVAX

NVAX Financial Statistics

Sales & Book Value

Annual Sales: $556.38M
Cash Flow: $-185.86M
Price / Cash Flow: 0
Annual Sales: $-5.14
Price / Book: 0

Profitability

EPS (TTM): -5.56000
Net Income (TTM): $-545.06M
Gross Margin: $212.61M
Return on Equity: 0%
Return on Assets: -30.48%

Novavax Earnings Forecast

Key Novavax Financial Ratios

  • The Gross Profit Margin over the past 25 years for NVAX is 38.21%.
  • The Selling, General & Administrative Expenses for NVAX have been equal to 84.28% of Gross Profit Margin.
  • The Research & Development expenses have been 132.55% of Revenue.
  • The Interest Expense is -2.64% of Operating Income.
  • The Net Earning history of NVAX is -97.97% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 13 years.

Novavax Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: NVAX
CUSIP: 670002
Website: novavax.com

Debt

Debt-to-Equity Ratio: -0.23
Current Ratio: 0.7
Quick Ratio: 0.53

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NVAX Technical Analysis vs Fundamental Analysis

Sell
27
Novavax (NVAX) is a Sell

Is Novavax a Buy or a Sell?

  • Novavax stock is rated a Sell
    The current Novavax [NVAX] share price is $4.84. The Score for NVAX is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.